Overview

The Expert Exchange is an engaging and dynamic format that encourages audience involvement and provides a flexible framework within which to incorporate rapidly-emerging data. This interactive symposium will feature several relevant case-based discussions with audience voting on ARS keypads. Case topics have been cultivated from top issues by expert faculty and will include an examination of the evolving role of checkpoint inhibition across various stages of the bladder cancer disease continuum, with particular emphasis on novel approaches in advanced disease. Expert faculty will also explore the latest evidence for managing disease progression, sequencing and/or combining ICI therapy with FGFR inhibitors and ADCs, the appropriate duration of treatment, and proactive strategies for anticipating and managing immune-related adverse events (irAEs) that may occur in bladder cancer patients taking checkpoint inhibitors.

Speakers

Robert Dreicer, MD, MS, MACP, FASCO

University of Virginia School of Medicine
Charlottesville, Virginia View Full Bio

Ashish Kamat, MD, MBBS, FACS

University of Texas, MD Anderson Cancer Center
Houston, Texas


View Full Bio

Accreditation

Medicine (ACCME)

CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacy (ACPE)

This application-based activity is approved for 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit (UAN JA0007101-0000-20-003-L01-P).

Nursing (ANCC)

This activity is designated for 1.5 contact hours.

Upon completion of a CE request form, statements of credit for physicians and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.

Acknowledgement

This activity is presented by Creative Educational Concepts, Inc. in collaboration with the Bladder Cancer Advocacy Network (BCAN).

This activity is supported through an independent educational grant from AstraZeneca.